ArticleOncotarget2019
Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The Prognostic Power of miR-21 in Breast Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Selective regulation of βMedical oncology (Northwood, London, England) · 2026Article
- Role and underlying mechanisms of miR‑200 family in breast cancer (Review).International journal of oncology · 2026Review
- MicroRNA Expression in Breast Cancer Patients, an Integrative Review.Journal of surgical oncology · 2026Review
- The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.The journal of liquid biopsy · 2025Review
- MicroRNAs as Endocrine Modulators of Breast Cancer.International journal of molecular sciences · 2025Review
- Circulating non-coding RNAs as a tool for liquid biopsy in solid tumors.Epigenomics · 2025Review
- MicroRNAs and their role in breast cancer metabolism (Review).International journal of oncology · 2025Review
- Value of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancer.Molecular biology reports · 2024Article
- Extracellular Vesicles-A Source of RNA Biomarkers for the Detection of Breast Cancer in Liquid Biopsies.Cancers · 2023Article
- Circulating microRNA Biomarker for Detecting Breast Cancer in High-Risk Benign Breast Tumors.International journal of molecular sciences · 2023Article
- Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms.International journal of molecular sciences · 2022Review
- Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.Archives of gynecology and obstetrics · 2022Article
- Circulating miR-141 as a potential biomarker for diagnosis, prognosis and therapeutic targets in gallbladder cancer.Scientific reports · 2022Article
- Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics.International journal of molecular sciences · 2022Review
- Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer.Cancers · 2022Article
- Review
- EMT in salivary gland tumors: the expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters.Molecular biology reports · 2022Article
- Potential utility of miRNAs for liquid biopsy in breast cancer.Frontiers in oncology · 2022Review
- Computational and Bioinformatics Methods for MicroRNA Gene Prediction.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating miRNAs (miRs) are increasingly recognized as potential biomarkers in cancer. We aimed to evaluate the differential expression of miR-23b and miR-190 which are involved in tumor dormancy, miR-21 involved in metastasis and miR-200b and miR-200c involved in epithelial-mesenchymal transition (EMT) and metastasis, in the plasma of patients with early and metastatic breast cancer (MBC). We also aimed to identify associations of the expression levels with patient and disease characteristics and outcomes in metastatic patients treated with first-line chemotherapy.
resultsmiR-21 ( MATERIALS AND
methodsBlood samples were obtained from patients with early (
conclusionsOur results are in support of the concept that circulating miRNAs represent a tool with significant diagnostic and prognostic implications in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.